With the completion of the human genome project, surges in studies investigating the association of antidepressant responsiveness and select polymorphisms have been conducted. Studies have been completed investigating polymorphisms in the monoaminergic system, including the serotonin transporter gene, the serotonin 1A, 2A, and 6 receptor genes, the G-protein-coupled receptor genes, the tryptophan hydroxylase 1 gene, the monoamine oxidase gene, the dopamine receptor genes, and the noradrenergic genes. Other genes of potential interest for investigation include the nitric oxide gene, the angiotensin-converting enzyme gene, the interleukin-1 beta gene, the stress hormone system, and the phosphodiesterase genes. Many of the studies have provided positive results, but the studies are small and are limited to a specific ethnicity. Further research is needed in the area before an array of genes can be used to predetermine response to antidepressant medication.
McCaig LFNational Hospital Ambulatory Medical Care Survey. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics , 1997; DHHS publication no (PHS)98-1250.
2.
200 Generic and Brand Drugs by Units in 2005 . Drug Topics March 6, 2006.
3.
200 Generic and Brand Drugs by Units in 2004 . Drug Topics February 21, 2005.
4.
Thase ME , Entsuah AR , Rudolph RLRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors . Br J Psychiatry. 2001 ;178: 234-241 .
5.
Thase ME , Haight BR , Richard N. , et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from seven randomized controlled trials . J Clin Psychiatry.2005;66: 974-981 .
6.
Mulrow CD , Williams JW Jr , Trivedi M. , et al. Treatment of depression-newer pharmacotherapies . Evid Rep Technol.1999;7: 1-4 .
7.
Lander ES , Linton LM , Birren B. , et al. Initial sequencing and analysis of the human genome . Nature. 2001;409: 860-921 .
8.
Venter JC , Adams MD , Myers EW , et al. The sequence of the human genome . Science. 2001;291: 1304-1351 .
9.
Pare C. , Rees L. , Saisbury M.Differentiation of two genetically specific types of depression by the response to antidepressants . Lancet. 1962 ;29: 1340-1343 .
10.
Angst J.A clinical analysis of the effects of tofranil in depression: longitudinal and follow-up studies. Treatment of blood-relation . Psychopharmacologia . 1961;2: 381-407 .
11.
O'Reilly RL , Bogue L. , Singh SMPharmacogenetic response to antidepressants in a multicase family with affective disorder . Biol Psychiatry.1994;36: 467-471 .
12.
Franchini L. , Serretti A. , Gasperini M. , Smeraldi E.Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees . J Psychiatr Res.1998;32: 255-259 .
13.
Mann JJThe medical management of depression . N Engl J Med.2005;353: 1819-1834 .
14.
Ramamoorthy S. , Leibach FH , Mahesh VB , Ganapathy V.Partial purification and characterization of the human placental serotonin transporter . Placenta. 1993;14: 449-461 .
15.
Lesch KP , Wolozin BL , Estler HC , Murphy DL , Riederer P.Isolation of a cDNA encoding the human brain serotonin transporter . J Neural Transm Gen Sect.1993;91: 67-72 .
16.
Lesch KP , Bengel D. , Heils A. , et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region . Science . 1996;274: 1527-1531 .
17.
Heils A. , Teufel A. , Petri S. , et al. Allelic variation of human serotonin transporter gene expression . J Neurochem.1996;66: 2621-2624 .
18.
Gelernter J. , Cubells JF , Kidd JR , Patkastis AJ , Kidd KKPopulation studies of polymorphisms of the serotonin transporter protein gene . Am J Med Genet.1999;88: 61-66 .
19.
Smeraldi E. , Zanardi R. , Benedetti F. , De Bella D , Perez J. , Catalano M.Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine . Mol Psychiatry. 1998;3: 508-511 .
20.
Zanardi R. , Benedetti F. , Di Bella D , Catalano M. , Smeraldi E.Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene . J Clin Psychopharmacol. 2000;20: 105-107 .
21.
Pollock BG , Ferrell RE , Mulsant Bh , et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression . Neuropsychopharmacology.2000;35: 587-590 .
22.
Arias B. , Catalan R. , Gastro C. , Gutierrez B. , Fananas L. 5- HTTLPR polymorphism of the serotonin transporter gene predicts nonremission in major depression patients treated with citalopram in a 12-weeks follow up study . J Clin Psychopharmacol. 2003;23: 563-567 .
23.
Zanardi R. , Serretti A. , Rossini D. , et al. Factors affecting fluvoxamine antidepressant activity; influence of pindolol and 5-HTTLPR in delusional and nondelusional depression . Biol Psychiatry.2001;50: 323-330 .
24.
Rausch JL , Johnson ME , Fei YJ , et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome . Biol Psychiatry . 2001;51: 723-732 .
25.
Joyce PR , Mulder RT , Luty SE , et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline . Int J Neuropsychopharmacol.2003;6: 339-346 .
26.
Durham LK , Webb SM , Milos PM , Clary CM , Seymour ABThe serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder . Psychopharmacology. 2004;174: 525-529 .
27.
Murphy GM Jr, Hollander SB , Rodrigues HE , Kremer C. , Schatzberg AFEffects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression . Arch Gen Psychiatry. 2004;61: 1163-1169 .
28.
Serretti A. , Cusin C. , Rossini D. , Artioli P. , Dotoli D. , Zanardi R.Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders . Am J Med Genet B Neuropsychiatr Genet.2004 ;129: 36-40 .
29.
Kraft JB , Slager SL , McGrath PJ , Hamilton SPSequence analysis of the serotonin transporter and associations with antidepressant response . Biol Psychiatry. 2005;58: 374-381 .
30.
Kim DK , Lim SW , Lee S. , et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine . Psychiatry Res.2002; 111: 253-259 .
31.
Ito K. , Yoshida K. , Sato K. , et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine . Psychiatry Res.2002; 111: 235-239 .
32.
Yoshida K. , Ito K. , Sato K. , et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients . Prog Neuropsychopharmacol Biol Psychiatry. 2002;26: 383-386 .
33.
Yu YW, TsaiSj, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders . Mol Psychiatry. 2002;7: 1115-1119 .
34.
Lee MS , Lee HY , Lee HJ , Ryu SHSerotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment . Psychiatr Genet.2004;14: 111-115 .
35.
Kato M. , Ikenaga Y. , Wakeno M. , et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism . Int Clin Psychopharmacol.2005;20: 151-156 .
36.
Kim H. , Lim SW , Seonwoo K. , et al. Monoamine transporter gene polymorphisms and antidepressant responses in Koreans with late-life depression . JAMA.2006;296: 1609-1618 .
37.
Rotondo A. , Nielson DA , Nakhai B. , Hulihan-Giblin B. , Bolos A. , Goldman D.Agonist-promoted down-regulation and functional desensitization in two naturally occurring variants of the human serotonin 1A receptor . Neuropsychopharmacology . 1997;17: 18-26 .
38.
Albert PR , Lembo P. , Storring JM , Charest A. , Saucier C.The 5-HT1A receptor: signaling, desensitization, and gene transcription . Neuropsychopharmacology. 1996;14: 19-25 .
39.
Kobilka BK , Frielle T. , Collins S. , et al. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins . Nature. 1987; 329: 75-79 .
40.
Erdmann J. , Shimron-Abarbanell D. , Cichon S. , et al. Systematic screening for mutations in the promoter and the coding region of the 5-HT1A gene . Am J Med Genet.1996; 60: 393-399 .
41.
Nakhai B. , Nielsen DA , Linnoila M. , Goldman D.Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28 . Biochem Biophys Res Commun.1995;210: 530-536 .
42.
Wu S. , Comings DEA common C-1018G polymorphism in the human 5-ht!A receptor gene . Psychiatr Genet.1999;9: 105-106 .
43.
Lemonde S. , Du L. , Bakish D. , Hrdina P. , Albert PRAssociation of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response . Int J Neuropsychopharmacol.2004;7: 501-506 .
44.
Arias B. , Catalan R. , Gastro C. , Gutierrez B. , Fananas L.Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with Citalopram . J Psychopharmacol. 2005;19: 166-172 .
45.
Sparkes RS , Lan N. , Klisak I. , et al. Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14 . Genomics. 1991;9: 461-465 .
46.
McMahon FJ , Buervenich S. , Charney D. , et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment . Am J Hum Genet.2006;78: 804-814 .
47.
Wu WH , Huo SJ , Cheng CY , Hong CJ , Tsai SJAssociation study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders . Neuropsychobiology. 2001;44: 172-175 .
48.
Serretti A. , Benedetti F. , Zanardi R. , Smeraldi E.The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments . Prog Neuropsychopharmacol Biol Psychiatry. 2005;29: 1074-1084 .
49.
Serretti A. , Lorenzi C. , Cusin C. , et al. SSRIs antidepressant activity is influenced by G beta 3 variants . Eur Neuropsychopharmacol.2003;13: 117-122 .
50.
Siffert W. , Rosskopf D. , Moritz A. , et al. Enhanced G protein activation immortalized lymphoblasts from patients with essential hypertension . J Clin Invest.1995;96: 759-766 .
51.
Lee HJ , Cha JH , Ham BJ , et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders . Pharmacogenomics J.2004;4: 29-33 .
52.
Zill P. , Baghai TC , Zwanzger P. , et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment . Neuroreport. 2000; 11: 1893-1897 .
53.
Craig SP , Boularand S. , Darmon MC , Mallet J. , Craig IWLocalization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization . Cytogenet Cell Genet.1991;56: 157-159 .
54.
Rotondo A. , Schuebel KE , Bergen AW , et al. Identification of four variants in the tryptophan hydroxylase promoter and association to behavior . Mol Psychiatry. 1999;4: 360-368 .
55.
Cote F. , Schussler N. , Boularand S. , et al. Involvement of NE-Y and Sp1 in basal and Camp-stimulated transcriptional activation of the tryptophan hydroxylase (TPH) gene in the pineal gland . J Neurochem.2002;81: 673-685 .
56.
Paoloni-Giacobino A. , Mouthon D. , Lambercy C. , et al. Identification and analysis of new sequence variants in the human tryptophan hydroxylase (TpH) gene . Mol Psychiatry. 2000;5: 49-55 .
57.
Nielson DA , Jenkins GL , Stefanisko KM , Jefferson KK , Goldman D.Sequence, splice site, and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7 . Brain Res Mol Brain Res. 1997;45: 145-148 .
58.
Serretti A. , Zanardi R. , Cusin C. , Rossini D. , Lorenzi C. , Smeraldi E.Tryptophan hydroxylase gene associated with paroxetine antidepressant activity . Eur Neuropsychopharmacol.2001;11: 375-380 .
59.
Serretti A. , Zanardi R. , Rossini D. , Cusin C. , Lilli R. , Smeraldi E.Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity . Mol Psychiatry. 2001;6: 586-592 .
60.
Peters EJ , Slager SL , McGrath PJ , Knowles JA , Hamilton SPInvestigation of serotonin-related genes in antidepressant response . Mol Psychiatry. 2004;9: 879-889 .
61.
Yoshida K. , Naito S. , Takahashi H. , et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder . Prog Neuropsychopharmacol Biol Psychiatry. 2002;26: 1279-1283 .
62.
Berry MD , Juorio AV , Paterson IAThe functional role of monoamine oxidase A and B in the mammalian central nervous system . Prog Neurobiol. 1994 ;42: 375-391 .
63.
Sabol SZ , Hu S. , Hamer D.A functional polymorphism in the monoamine oxidase A gene promoter . Hum Genet.1998;103: 273-279 .
64.
Denney RM , Kock H. , Craig IWAssociation between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter associated variable number tandem repeats . Hum Genet.1999;105: 542-551 .
65.
Muller DJ , Schulze TG , Macciardi F. , et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter . Pharmacopsychiatry. 2002;35: 157-158 .
66.
Cusin C. , Serretti A. , Zanardi R. , et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity . Int J Neurpsychopharmacol.2002;5: 27-35 .
67.
Serretti A. , Zanardi R. , Cusin C. , et al. No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective reuptake inhibitors . Psychiatry Res.2001;104: 195-203 .
68.
Manji HK , Lennox RHSignaling: cellular insights into the pathophysiology of bipolar disorder . Biol Psychiatry. 2000; 48: 518-530 .
69.
Mason DA , Moore JD , Green SA , Liggett SBA gain-of-function polymorphism in a g-protein coupling domain of the human beta1 adrenergic receptor . J Biol Chem.1999 ;274: 12670-12674 .
70.
Zill P. , Baghai TC , Engel R. , et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response . Am J Med Genet.2003;120B: 85-89 .
71.
Karatinos J. , Rosse RB , Deutsch SIThe nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders . Clin Neuropharmacol.1995;18: 482-499 .
72.
Finkel MS , Laghrissi-Thode F. , Pollock BG , Rong J.Paroxetine is a novel nitric oxide synthase inhibitor . Psychopharmacol Bull.1996;32: 653-658 .
73.
Shinkai T. , Ohmori O. , Hori H. , Nakamura J.Allelic association of the neuronal nitric oxide synthase (NOS 1) gene with schizophrenia . Mol Psychiatry. 2002 ;7: 560-563 .
74.
Yu YW , Chen TJ , Wang YC , Liou YJ , Hong CJ , Tsai SJAssociation analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response . Neuropsychobiology.2003;47: 137-140 .
75.
Serretti A. , Artioli P. , Quartesan R.Pharmcogenetics in the treatment of depression: pharmacodynamic studies. PharmacogenetGenom.2005;15: 61-67 .
76.
Vuckovic A. , Cohen BM , Zubenko GSThe use of captopril in treatment-resistant depression: an open trial . J Clin Psychopharmacol . 1991;11: 395-396 .
77.
Arregui A. , MacKay AV , Iversen LL , Spokes EGReduction of angiotensin-converting enzyme in substania nigra in early-onset schizophrenia . N Engl J Med.1979;300: 502-503 .
78.
Jeffery S. , Saggar Malik AK , Crosby A. , et al. A dominant relationship between the ACE D allele and serum ACE levels in a Ghanaian population . J Med Genet.1999;36: 869-870 .
79.
Baghai TC , Schule C. , Zwanzger P. , et al. Possible influence of the insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene on therapeutic outcome in affective disorders . Mol Psychiatry. 2001;6: 258-259 .
80.
Hong CJ , Wang YC , Tsai SJAssociation study of angiotensin 1-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders . J Neural Transm.2002;109: 1209-1214 .
81.
Serretti A. , Artioli P.The pharmacogenomics of selective serotonin reuptake inhibitors . Pharmacogenomics J.2004 ;4: 233-244 .
82.
Owen B. , Eccleston D. , Ferrier I. , Young A.Raised levels of plasma interleukin-1 in major and post viral depression . Acta Psychiatr Scand.2000;103: 226-228 .
83.
Maes M. , Bosmans E. , Meltzer HY , Scharpe S. , Suy E.Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?Am J Psychiatry.1993;150: 1189-1193 .
84.
Anisman H. , Ravindran AV , Griffiths J. , Merali Z.Endocrine and cytokine correlates of major depression and dysthymia with typical and atypical features . Mol Psychiatry. 1999 ;4: 182-188 .
85.
Anisman H. , Kokkinidis L. , Meralis Z.Further evidence for the depressive effects of cytokines: anhedonia and neuro-chemical changes . Brain Behav Immun. 2002;16: 544-556 .
86.
Maes M.Major depression and activation of the inflammatory response system . Adv Exp Med Biol. 1999;461: 25-46 .
87.
Di Giovine F , Takhsh E. , Blakemore A.Single base polymorphism at —511 in the human interleukin-1 gene (IL1) . Hum Mol Genet.1992;1: 450 .
88.
Pociot F. , Molvig J. , Wogensen L. , Worsaae H. , Nerup J.A Taq1 polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro . Eur J Clin Invest.1992;22: 396-402 .
89.
Guasch JF , Bertina RM , Reitsma PHFive novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity . Cytokine. 1996 ;8: 598-602 .
90.
Yu YW , Chen TJ , Hong CJ , Chen HM , Tsai SJAssociation study of the interleukin-1 beta (c-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response . Neuropsychopharmacology. 2003;28: 1182-1185 .
Licinio J. , O'Kirwan F. , Irizarry K. , et al. Association of a corticotrophin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans . Mol Psychiatry.2004;9: 1075-1082 .
93.
van Rossum ECF , Binder EB , Mayer M. , et al. Polymorphisms of the glucocorticoid receptor gene and major depression . Biol Psychiatry. 2006;59: 681-688 .
94.
Binder EB , Salyakina D. , Lichtner P. , et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment . Nat Genet.2004;36: 1319-1325 .
95.
Perry MJ , Higgs GAChemotherapeutic potential of phosphodiesterase inhibitors . Curr Opin Chem Biol. 1998;2: 472-481 .
96.
Beavo JA , Brunton LLCyclic nucleotide research-still expanding after half a century . Nat Rev Mol Cell Biol.2002;3: 710-718 .
97.
Bolger GBMolecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes . Cell Signal.1994;6: 851-859 .
98.
Houslay MD , Adams DRPDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signaling cross talk, desensitization and compartmentalization . Bio Chem J.2003;370: 1-18 .
99.
Zhang HT , O'Donnell JM. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats . Psychopharmacology (Berl).2000;150: 311-316 .
100.
Zhang HT , Crissman AM , Dorairaj NR , Chandler LJ , O'Donnell JM. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism . Neuropsychopharmacology.2000;23: 198-204 .
101.
Perez J. , Tardito D. , Racagni G. , Smeraldi E. , Zanardi R.Protein kinase A and Rap 1 levels in platelets of untreated patients with major depression . Mol Psychiatry. 2001 ;6: 44-49 .
102.
O'Donnell JM , Frith S. , Wilkins J.Involvement of beta-1 and beta-2 adrenergic receptors in the antidepressant-like effects of centrally administered isoproterenol . J Pharmacol Exp Ther.1994;271: 246-254 .
103.
Zhang HT , Huang Y. , Jin SL , et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in PDE4D phosphodiesterase enzyme . Neuropsychopharmacology . 2002;27: 587-595 .
104.
Wong ML , Whelan F. , Deloukas P. , et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response . PNAS . 2006;103: 15124-15129 .
105.
Murphy GM Jr, Hollander SB , Rodrigues HE , Kremer C. , Schatzberg AFEffects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression . Arch Gen Psychiatry. 2004;61: 1163-1169 .
106.
Minov C. , Baghi TC , Schule C. , et al. Serotonin-2A-receptor and —transporter polymorphisms: lack of association in patients with major depression . Neurosci Lett. 2001;303: 119-122 .
107.
Hong CJ , Chen TJ , Yu YW , Tsai SJResponse to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder . Pharmacogenomics J.2006;6: 27-33 .
108.
Serretti A. , Artioli P. , Lorenzi C. , Pirovano A. , Tubaio V. , Zanardi R.The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings . Int J Neuropsychopharmacol.2004; 7: 453-460 .
109.
Yu YW , Tsai SJ , Liou YJ , Hong CJ , Chen TJAssociation study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders . Eur Neuropsychopharmacol.2006;16: 498-503 .
110.
Yoshida K. , Takahashi H. , Higuchi H. , et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms . Am J Psychiatry.2004;161: 1575-1580 .
111.
Sato K. , Yoshida K. , Takahashi H. , et al. Association between —1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder . Neuropsychobiology. 2002;46: 136-140 .
112.
Baghai TC , Schule C. , Zill P. , et al. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men . Neurosci Lett. 2004;363: 38-42 .
113.
Spina E. , Gitto C. , Avenoso A. , Campro GM , Caputi AP , Perucca E.Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study . Eur J Clin Pharmacol.1997;51: 395-398 .
114.
Laika B. , Leucht S. , Steimer W.ABCB1 (p-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association of side effects and the therapeutic response in depressed inpatients treated with amitriptyline . Clin Chem.2006;52: 893-895 .
115.
Roberts RL , Joyce PR , Mulder RT , Begg EJ , Kennedy MAA common p-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression . Pharmacogenomics J.2002;2: 191-196 .
116.
de Leon J. , Armstrong SC , Cozza KLClinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19 . Psychosomatics.2006;47: 75-85 .
